A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of hLAG-3 Fusion Protein, EOC202 (Eftilagimod Alpha) Combined With Paclitaxel in Chinese Patients With Metastatic Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 13 May 2019
Price : $35 *
At a glance
- Drugs Eftilagimod alpha (Primary) ; Paclitaxel (Primary) ; Dexamethasone
- Indications Advanced breast cancer; Carcinoma
- Focus Adverse reactions
- Sponsors EOC Pharma
- 07 May 2019 Status changed from not yet recruiting to recruiting.
- 04 May 2019 Planned primary completion date changed from 31 May 2019 to 31 Aug 2019.
- 08 Aug 2018 According to an Immutep Limited media release, the study is expected to initiate in 3Q 2018.